Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1935 Views
eMediNexus 26 February 2018
Calcium channel blockers (CCBs) are the choice of therapy for post-stroke patients. A large-scale prospective study of 2667 post-stroke hypertensive patients treated with cilnidipine assessed BP control and adverse reactions in the patients. Cilnidipine treatment led to a reduction in both clinic and home BP 2 months after treatment initiation. The decreased BP was maintained until the end of 12 months of observation. The proportion of patients with well controlled clinic BP (<140/90 mmHg) rose from 21.5% to 65.3% with cilnidipine treatment, with no differences seen in effectiveness across the various clinical subtypes of stroke. In all, 346 adverse events occurred, with an overall incidence of 8.9% (238 of 2667 patients). Cilnidipine effectively treated uncontrolled BP and was well tolerated in post-stroke hypertensive patients in a real-world clinical setting. The results were published in Clinical and Experimental Hypertension.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}